Project CASK Named Collaborator in Critical Path Institute 2026 BRIDGe Program for CASK Gene Disorder Drug Development

Project CASK has been named a collaborator supporting the Critical Path Institute's Translational Therapeutics Accelerator (TRxA) 2026 BRIDGe program — a competitive drug development initiative that connects academic investigators with resources to advance rare disease research toward the clinic.

The Critical Path Institute (C-Path) is an independent, nonprofit organization that works in close collaboration with the U.S. Food and Drug Administration (FDA) to drive the development of new approaches to medical product development. C-Path's TRxA program is specifically designed to accelerate translational research for rare and neglected diseases.

C-Path's 2026 BRIDGe program press release states: 'C-Path is pleased to recognize additional collaborators supporting this year's BRIDGe effort, including Project CASK, who are working with us to help bring additional funding to projects focused on CASK-related disorders.'

The BRIDGe program provides academic investigators with funding and expert guidance to advance drug development projects for rare diseases. Project CASK's role as a named collaborator reflects the organization's growing presence at the intersection of parent advocacy and translational drug development.

This collaboration represents a significant step in Project CASK's mission to move CASK gene disorder research from laboratory discovery toward clinical application. Working alongside C-Path's regulatory and drug development expertise, Project CASK continues to build the infrastructure and partnerships needed to make treatments for CASK gene disorders a reality.

About Critical Path Institute

The Critical Path Institute is an independent, nonprofit organization headquartered in Tucson, Arizona. C-Path works in close collaboration with the FDA and international regulatory agencies to improve the medical product development process. C-Path's Translational Therapeutics Accelerator (TRxA) program specifically supports rare disease drug development through competitive funding and expert guidance.

Read the full C-Path press release at c-path.org.